Center for Human Genetics

The Center for Human Genetics (Centrum Menselijke Erfelijkheid) is active in three domains: research, teaching and health services. The center focuses on hereditary diseases, cancer and neurological disorders. Its collaborators want to gain a better insight into these diseases, in order to assure patients a correct and timely diagnosis and a better treatment and support.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

news image

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More

GSK STARTS PHASE 2/3 STUDY OF COVID-19 ANTIBODY TREATMENT WITH VIR BIOTECHNOLOGY

GlobeNewswire | September 01, 2020

news image

-Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization. The aim of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study, which will enroll approximatel...

Read More

MEDICAL

RESILIENCE AND MD ANDERSON LAUNCH JOINT VENTURE TO ACCELERATE DEVELOPMENT AND MANUFACTURING OF INNOVATIVE CELL THERAPIES FOR CANCER

Resilience | June 07, 2022

news image

National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture will advance its work within a culture of academic innovation alongside industrial expertise. The Cell Therapy Manufacturing Center ...

Read More

MEDICAL

SELFDECODE OFFERS FREE KIDNEY HEALTH DNA REPORT TO CELEBRATE NATIONAL KIDNEY MONTH

SELFDECODE | March 07, 2022

news image

SelfDecode is kicking off National Kidney Month with a national campaign to raise awareness about the importance of preventative measures to optimize kidney health. For the month of March, SelfDecode is offering a free Kidney Health DNA Report to anyone who uploads a DNA file for analysis. Through genetic testing, SelfDecode is providing people with the opportunity to gain insight regarding their genetic predisposition for health issues and receive personalized recommendations to ...

Read More
news image

MEDICAL

MINDMED ANNOUNCES THE START OF THE FIRST EVER CLINICAL TRIAL MEASURING AND EVALUATING MDMA AND LSD

MindMed | January 21, 2021

MindMed, a main psychedelic medication biotech organization, reported today the beginning of the principal ever clinical preliminary estimating and assessing MDMA and LSD utilized in mix in the human body. The preliminary will be directed at the University Hospital Basel Liechti Lab, in Basel, Switzerland. If administered in combination with LSD, MDMA may expand positive abstract medication impacts, including positive state of mood and empathy, and lessen the negative feelings and...

Read More
news image

GSK STARTS PHASE 2/3 STUDY OF COVID-19 ANTIBODY TREATMENT WITH VIR BIOTECHNOLOGY

GlobeNewswire | September 01, 2020

-Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc announced that the first patient was dosed last week in a Phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) monoclonal antibody, for the early treatment of COVID-19 in patients who are at high risk of hospitalization. The aim of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study, which will enroll approximatel...

Read More
news image

MEDICAL

RESILIENCE AND MD ANDERSON LAUNCH JOINT VENTURE TO ACCELERATE DEVELOPMENT AND MANUFACTURING OF INNOVATIVE CELL THERAPIES FOR CANCER

Resilience | June 07, 2022

National Resilience, Inc. (Resilience) and The University of Texas MD Anderson Cancer Center today announced the launch of a joint venture, the Cell Therapy Manufacturing Center, to accelerate the development and manufacturing of innovative cell therapies for patients with cancer. Uniting the strengths of Resilience and MD Anderson, the joint venture will advance its work within a culture of academic innovation alongside industrial expertise. The Cell Therapy Manufacturing Center ...

Read More
news image

MEDICAL

SELFDECODE OFFERS FREE KIDNEY HEALTH DNA REPORT TO CELEBRATE NATIONAL KIDNEY MONTH

SELFDECODE | March 07, 2022

SelfDecode is kicking off National Kidney Month with a national campaign to raise awareness about the importance of preventative measures to optimize kidney health. For the month of March, SelfDecode is offering a free Kidney Health DNA Report to anyone who uploads a DNA file for analysis. Through genetic testing, SelfDecode is providing people with the opportunity to gain insight regarding their genetic predisposition for health issues and receive personalized recommendations to ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us